GLP-1 RA DI Flashcards
GLP-1 RA MoA
suppresses glucagon secretion, increases insulin secretion, slows gastric emptying, promotes beta-cell proliferation
GLP-1 RA drugs with daily dosing
Exenatide (Byetta), Liraglutide (Victoza), Lixisenatide (Adylxin), PO semaglutide (Rybelsus)
GLP-1 RA drugs with weekly dosing
Exenatide (Bydureon, Bydureon BCise), dulaglutide (Trulicity), SQ semaglutide (Ozempic)
Exenatide brand names
Byetta (once daily), Bydureon, Bydureon BCise (once weekly)
Liraglutide brand name
Victoza
Lixisenatide brand name
Adylxin
Semaglutide brand names
Rybelsus (PO), Ozempic (SQ)
Dulaglutide brand name
Trulicity
Byetta dosing
5mcg SQ QD
Liraglutide dosing
0.6mg SQ
Lixisenatide dosing
10mcg SQ for 14 days, then 20mcg
Rybelsus dosing
3mg PO for 30 days, then 7mg PO, then 14mg PO
Bydureon dosing
2mg weekly
Dulaglutide dosing
0.75mg weekly, then 1.5mg, then 3mg, then 4.5mg
Ozempic dosing
0.25mg weekly, then 0.5mg, then 1mg
Pre-filled multiple dose pens
Byetta, Victoza, Adylxin, Ozempic
Pre-filled single-use pens
Bydureon, Trulicity
GLP-1 RA side effects
N/V/D, GERD, dyspepsia
GLP-1 RA BBW
thyroid C-cell tumor/cancer (lixisenatide is the only one that doesn’t have this BBW)
GLP-1 RA CI
Severe GI disease, CrCl <30 mL/min for exenatide
GLP-1 RA counseling
May cause upset stomach but should go away over time, store in fridge before use but leave at room temperature after first use, take Rybelsus 30 minutes before first meal, take with as little water as possible
What should you ask about at GLP-1 RA refills?
GI upset and dose timing
GLP-1 RA pearls
High A1C lowering, no hypoglycemia, weight LOSS, neutral effect on HF, improved renal outcomes with liraglutide and dulaglutide
GLP-1 RA renal dosing
Exenatide and lixisenatide
GLP-1 RAs that are effective in Black patients
Lixisenatide and semaglutide
GLP-1 RA monitoring
A1C, FBG/PPG, renal function, GI symptoms, patient use of device
GLP-1 RA peak effect
6-8 weeks
ADA guidelines on GLP-1 RA
Use when ASCVD risk is present, to minimize hypoglycemia, and weight loss
AACE guidelines on GLP-1 RA
Second-line after metformin